Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Coya Therapeutics, Inc. - Common Stock (NQ: COYA ) 7.260 +0.520 (+7.72%) Official Closing Price Updated: 4:15 PM EST, Nov 6, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Coya Therapeutics, Inc. - Common Stock < Previous 1 2 3 4 Next > Coya Therapeutics Provides a Corporate Update and Reports Unaudited Third Quarter 2024 Financial Results Today 8:00 EST From Coya Therapeutics, Inc. Via Business Wire Coya Therapeutics Announces Arun Swaminathan, Ph.D. Assumes New Role as Chief Executive Officer November 01, 2024 From Coya Therapeutics, Inc. Via Business Wire Coya Therapeutics Announces Positive Results of a Double-Blind Study of Subcutaneous Low-Dose Interleukin-2 (LD IL-2) in Alzheimer’s Disease (AD) Presented at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24) in Madrid (Spain) October 29, 2024 From Coya Therapeutics, Inc. Via Business Wire Coya Therapeutics Announces Conference Call to Report Results from an Investigator-Initiated Phase 2 Trial of Low-Dose Interleukin-2 in Patients with Mild to Moderate Alzheimer’s Disease October 28, 2024 From Coya Therapeutics, Inc. Via Business Wire Coya Therapeutics Announces Closing of $10.0 Million Private Placement October 23, 2024 From Coya Therapeutics, Inc. Via Business Wire Coya Therapeutics Announces $10.0 Million Private Placement October 22, 2024 From Coya Therapeutics, Inc. Via Business Wire Coya Therapeutics Chairman and CEO Howard Berman Selected for PharmaVoice 100 October 08, 2024 From Coya Therapeutics, Inc. Via Business Wire Coya Therapeutics to Participate in Fireside Chat at the Chardan 8th Annual Genetic Medicines Conference September 24, 2024 From Coya Therapeutics, Inc. Via Business Wire Coya Therapeutics Announces Subcutaneously Administered COYA 302 Elicits Direct Anti-Inflammatory Effect in Brain in a Preclinical Inflammatory Mouse Model of Parkinson’s Disease September 16, 2024 From Coya Therapeutics, Inc. Via Business Wire Coya Therapeutics to Present at Upcoming Healthcare Conferences September 03, 2024 From Coya Therapeutics, Inc. Via Business Wire Coya Therapeutics Promotes Arun Swaminathan Ph.D. to Chief Executive Officer Effective November 1st, 2024 August 19, 2024 From Coya Therapeutics, Inc. Via Business Wire Coya Therapeutics Provides a Corporate Update and Reports Unaudited Second Quarter 2024 Financial Results August 12, 2024 From Coya Therapeutics, Inc. Via Business Wire Coya Therapeutics Announces that Results from a Double-Blind Placebo-Controlled Study in Alzheimer’s Disease will be presented on October 29, 2024 at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24) in Madrid August 02, 2024 From Coya Therapeutics, Inc. Via Business Wire Coya Therapeutics Expands Pipeline and Intellectual Property Portfolio with Filing of New U.S. Patents for COYA 301 in Combination with Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists July 31, 2024 From Coya Therapeutics, Inc. Via Business Wire Coya Therapeutics Expands Sponsored Research Collaboration with Houston Methodist Research Institute Along with Funding from the Johnson Center for Cellular Therapeutics to Advance Regulatory T Cell Exosome Platform into the Clinic June 20, 2024 From Coya Therapeutics, Inc. Via Business Wire Coya Therapeutics Announces Publication of ALS Study in Peer-Reviewed Journal Frontiers in Neurology June 11, 2024 From Coya Therapeutics, Inc. Via Business Wire Coya Therapeutics Announces Acceptance of Peer-Reviewed Manuscript in the Medical Journal: Frontiers in Neurology June 03, 2024 From Coya Therapeutics, Inc. Via Business Wire Coya Therapeutics Announces Inclusion in the MSCI USA Micro Cap Index May 28, 2024 From Coya Therapeutics, Inc. Via Business Wire Coya Therapeutics Announces the Completion of a Controlled Phase 2 Study of Low Dose Interleukin-2 (LD IL-2) in Patients with Alzheimer’s Disease May 22, 2024 From Coya Therapeutics, Inc. Via Business Wire Coya Therapeutics Announces $5 Million Strategic Investment by the Alzheimer’s Drug Discovery Foundation (ADDF) May 20, 2024 From Coya Therapeutics, Inc. Via Business Wire Coya Therapeutics Provides a Corporate Update and Reports Unaudited First Quarter 2024 Financial Results May 09, 2024 From Coya Therapeutics, Inc. Via Business Wire Coya Therapeutics Presents Updated ALS Biomarker Data at the 2nd Annual Johnson Center Symposium April 26, 2024 From Coya Therapeutics, Inc. Via Business Wire Coya Therapeutics to Participate in the Mizuho Neuroscience Summit April 22, 2024 From Coya Therapeutics, Inc. Via Business Wire Coya Therapeutics to Participate in the 3rd Annual ALS Drug Development Summit April 18, 2024 From Coya Therapeutics, Inc. Via Business Wire Coya Therapeutics Scientific Advisory Board Chairman Dr. Stanley Appel to Present Updated ALS Biomarker Data at the 2nd Annual Johnson Center Symposium April 08, 2024 From Coya Therapeutics, Inc. Via Business Wire Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2023 Financial Results March 19, 2024 From Coya Therapeutics, Inc. Via Business Wire Coya Therapeutics to Participate in BTIG Fireside Discussion March 12, 2024 From Coya Therapeutics, Inc. Via Business Wire Coya Therapeutics Presents ALS Biomarker Data at Society of Neuroimmune Pharmacology Conference March 12, 2024 From Coya Therapeutics, Inc. Via Business Wire Coya Therapeutics Presents Biomarker Data on Neuroinflammatory Pathways in Frontotemporal Dementia (FTD) at the AD/PD 2024 Conference March 06, 2024 From Coya Therapeutics, Inc. Via Business Wire Coya Therapeutics to Present Data on Immune System and Regulatory T Cell (Treg) Contributions in Frontotemporal Dementia (FTD) Patients at AD/PD 2024 Conference February 29, 2024 From Coya Therapeutics, Inc. Via Business Wire < Previous 1 2 3 4 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
